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Abstract
Pancreatic neuroendocrine tumors (PanNETs) are a relatively rare but clinically challenging tumor type. In particular, high
grade, poorly-differentiated PanNETs have the worst patient prognosis, and the underlying mechanisms of disease are
poorly understood. In this study we have identified and characterized a previously undescribed class of poorly differentiated
PanNETs in the RIP1-Tag2 mouse model. We found that while the majority of tumors in the RIP1-Tag2 model are well-
differentiated insulinomas, a subset of tumors had lost multiple markers of beta-cell differentiation and were highly invasive,
leading us to term them poorly differentiated invasive carcinomas (PDICs). In addition, we found that these tumors
exhibited a high mitotic index, resembling poorly differentiated (PD)-PanNETs in human patients. Interestingly, we identified
expression of Id1, an inhibitor of DNA binding gene, and a regulator of differentiation, specifically in PDIC tumor cells by
histological analysis. The identification of PDICs in this mouse model provides a unique opportunity to study the pathology
and molecular characteristics of PD-PanNETs.
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Introduction
Pancreatic neuroendocrine tumors (PanNETs) are a rare but
clinically challenging tumor type; a consequence of marked disease
heterogeneity and limited understanding of the molecular basis for
these cancers, among other factors. PanNETs arise from cells of
the neuroendocrine system within the pancreas and include
insulinomas, gastrinomas, glucagonomas, VIPomas and somatos-
tatinomas [1]. Well-differentiated, low to medium grade PanNETs
can be classified into two groups: functional tumors that secrete
hormone, which represent 30% of patients, and nonfunctional
tumors which do not secrete hormone [2]. Well-differentiated
PanNETs are clinically distinct from poorly differentiated, high-
grade PanNETs (PD-PanNETs), which are characterized by a
high mitotic index [3].
PanNETs are the second most common pancreatic neoplasms,
representing approximately 1.3% of pancreatic cancers in
incidence and 10% of cases in prevalence [4]. PanNETs have
diverse clinical outcomes, in which some patients can exhibit long-
term survival, although the overall 10-year survival rate is only
40%. PanNET patients with nonfunctioning tumors constitute a
disproportionate number of patients with poor prognosis, as they
grow silently and present with extensive metastatic disease at
diagnosis. Patients with PD-PanNETs represent the worst
prognosis of the entire PanNET spectrum [5].
It is currently unknown whether nonfunctioning tumors and
PD-PanNETs arise from a different cell of origin to hormone-
producing neoplasms, or reflect a more stem-like differentiation
status [1]. While it is generally accepted that well-differentiated
PanNETs arise from the various neuroendocrine cells of the
pancreas, the cell of origin for poorly differentiated PanNETs is
controversial. It has been proposed that PD-PanNETs may in fact
originate from a separate, potentially non-neuroendocrine lineage
[3]. Therefore, insights into PanNET tumorigenesis from animal
models may be informative in discriminating between these
different possibilities.
The RIP1-Tag2 (RT2) mouse model of islet-cell carcinoma has
proven very instructive in studying neuroendocrine tumor
progression, and in particular, in predicting clinical efficacy of
new therapeutics [6]. In this model, beta-cell specific expression of
the SV40 T-antigen leads to islet-cell carcinomas through a
reproducible and well-characterized tumor progression pathway
[7]. The RT2 mouse model utilizes a viral oncogene, SV40 T-
antigen, to inactivate the p53 and retinoblastoma (Rb) tumor
suppressor pathways and induce tumorigenesis in pancreatic islet
cells. While this is not the mechanism of tumor initiation in
humans, a recent study has shown that negative regulators of the
p53 pathway are aberrantly activated in approximately 70% of
PanNETs [8]. Increased levels of these negative regulator proteins,
MDM2, MDM4 and WIP1, thus leads indirectly to a decrease in
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p53 activity [8]. In addition, another recent study showed that
68% of PanNET tumor samples examined exhibited attenuation
of the Rb pathway, via increased CDK4/6 [9]. Therefore, the
RT2 model inactivates the same tumor suppressor pathways as
genetic alterations observed in a majority of PanNET patients.
Several different classes of tumor grade have been reported in
the RT2 model including encapsulated tumors, microinvasive and
invasive carcinomas, which are thought to represent a multi-stage
progression series [10,11]. In addition, a previous study has
suggested that a subset of tumors may arise through a separate
pathway [12]. Through miRNA profiling of a panel of tumors and
metastases, they identified a subset of tumors whose gene
expression signature clusters closely with that of liver metastases,
and termed these ‘‘met-like primary’’ (MLP) tumors. It was
proposed that these MLPs most likely occur through a divergent
branch during tumorigenesis [12], separate from the prototypical
progression from encapsulated to invasive classes of tumors.
In this study, we have identified and characterized a previously
undescribed class of poorly differentiated PanNETs in the RT2
model. We found that while the majority of tumors in the RT2
model are well-differentiated insulinomas, a subset of tumors were
found to be poorly differentiated and highly invasive, leading us to
term them poorly differentiated invasive carcinomas (PDICs).
These tumors had lost expression of multiple markers of beta-cell
differentiation. In addition, we found that these tumors exhibited a
high mitotic index, resembling PD-PanNETs in human patients.
We also identified the inhibitor of differentiation/inhibitor of
DNA binding gene Id1 as being specifically expressed by these
tumors by histological analysis, and also to be expressed in ‘‘met-
like primary’’ tumors. The identification of PDICs provides a
unique opportunity to study the pathology and molecular
characteristics of PD-PanNETs in an experimental model.
Results
Identification of a novel class of invasive, poorly
differentiated tumors
During the course of analysis of serially sectioned pancreata
from RT2 mice, we identified a previously undescribed class of
tumors. These tumors were found histologically due to their high
nuclear to cytoplasmic ratio, anaplastic morphology and extensive
invasion into the surrounding normal exocrine pancreas
(Figure 1A). While the majority of insulinoma tumors in RT2
mice express high levels of insulin, these highly invasive tumors
were found to lack insulin expression, consistent with their poorly
differentiated appearance (Figure 1B). These tumors appeared to
be a distinct class of tumors from the invasive classes previously
described in this model [10], leading us to term these tumors
poorly differentiated invasive carcinomas (PDICs).
Discovery of a set of tumors that had lost insulin expression was
surprising, as it had been previously thought that all RT2 tumors
expressed insulin at high levels due to their origin from beta-cells.
By H&E staining the PDICs appeared to be PanNETs, however
there remained the possibility that these arose from a different cell
of origin and were not PanNETs. To determine whether they were
still driven by the SV40 T-antigen oncogene, which induces
tumorigenesis in beta-cells under control of the rat insulin
promoter (RIP) [7], we stained sections with a T-antigen antibody,
and found that all tumors expressed T-antigen, including all
PDICs that had lost insulin expression (Figure 1C).
PDICs exhibit a high mitotic index
High-grade PanNETs in patients are characterized by their
high mitotic index [3]. Therefore, we were interested in whether
these PDICs also exhibited an increased mitotic index. As shown
in Figure 2A, PDICs that have lost insulin (shown in the inset),
have a markedly higher proportion of cells that are Ki67 positive,
as compared to tumors that maintain insulin expression, shown on
the right side of the image. Co-staining of insulin and Ki67
confirmed that PDICs which have lost insulin exhibit a higher
mitotic index compared to tumors that maintain insulin expression
(Figure 2B). We quantified the mitotic index in PDICs compared
to insulinomas and found that PDICs exhibited a significantly
higher mitotic index, with greater than 80% of all cells being
Ki67+ (Figure 2C). Therefore, PDICs in the RT2 model are highly
proliferative, similar to poorly differentiated, high-grade PanNET
tumors in patients.
PDICs occur in the majority of RT2 mice
PDICs have not been previously described in the RT2 model
and it was unknown whether these tumors were rare or present in
all mice but had been previously missed. To thoroughly investigate
the frequency of PDICs, we completely sectioned through the
entire pancreas of RT2 mice and examined every 10th slide to
ensure that each tumor throughout the tissue was represented and
analyzed. When staining for insulin, we found that while all mice
had seven to ten insulinomas each, 70% of WT RT2 mice
examined also had at least one PDIC. Thus, our analysis has
revealed that PDICs are actually not uncommon, constituting
10.3% of all tumors (Table 1).
PDICs exhibit loss of neuroendocrine markers
Given the loss of insulin expression in PDICs, we next
investigated whether other markers of beta-cells and neuroendo-
crine cells were also absent in these tumors. Tissue sections
containing both PDICs and insulinomas were stained for a panel
of cell type-specific markers [13,14]. Synaptophysin, a marker of
neuroendocrine cells, was found to be generally expressed in both
insulinomas and PDICs, indicating that these tumors still
maintained aspects of neuroendocrine differentiation, however
some PDICs exhibited heterogeneous downregulation (Figure 3).
An additional neuroendocrine marker, chromogranin A, was
found to be completely absent in PDICs. Moreover, the
transcription factors MafA, Nkx6.1 and Pdx1 were also absent
in PDICs (Figure 3). Therefore, while PDICs maintain some
aspects of neuroendocrine cell differentiation, they exhibit loss of
multiple markers of b-cell differentiation.
As PDICs have lost expression of beta-cell specific genes, it
raised the possibility that they are tumors that have arisen from
one of the other neuroendocrine cell types that constitute
pancreatic islets. While beta-cells represent the major cell type in
islets, alpha-cells and delta-cells are also present, and tumors such
as glucagonomas and somatostatomas can arise from these cells
[1]. Also, it has previously been shown that under extreme beta-
cell loss, alpha-cells can be converted into beta-cells [15],
indicating that there can be plasticity between the different
neuroendocrine cell types of the islets. Therefore, it is also possible
that these tumors could reflect the converse situation, in which
beta-tumor cells trans-differentiate into one of the other pancreatic
neuroendocrine cell types. To address this possibility, we stained
tissue sections for glucagon, a marker of alpha-cells, and
somatostatin, a marker of delta-cells. We saw that normal islets
exhibited a small proportion of cells that stained positive for these
cell markers, as expected. Alpha- and delta-cells were also
observed in tumors, albeit at a lower frequency, as they were
displaced by hyperproliferation of the tumor cells (Figure 4A, B).
However, we saw that there was no glucagon or somatostatin
staining of tumor cells in PDICs (Figure 4A, B), indicating that
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PDICs lack expression of all pancreatic neuroendocrine cell type-
specific markers. Finally, as it has been suggested that pancreatic
acinar cells may serve as progenitor cells for pancreatic islets
[16,17], we investigated whether PDICs showed any evidence of
exocrine cell expression. We examined expression of elastase, a
digestive enzyme produced by the acinar cells [18] (Figure 4C).
Exocrine cells surrounding PDICs stained positively for elastase, as
expected. We found no evidence for elastase staining in tumor cells
Figure 1. Identification of poorly differentiated invasive carcinomas (PDICs). (A) H&E staining of paraffin tissue sections demonstrates a
tumor region with an anaplastic appearance and a high nuclear to cytoplasm ratio. 406magnification of the boxed region is shown in the right
panel. T = Tumor, E = Exocrine pancreas. Scale bars: 100 mm (left), 20 mm (right). (B) IHC for insulin was performed on paraffin sections from RT2 mice,
and representative images are shown. While the majority of the tumors (labeled insulinoma) produce high levels of insulin (detected by DAB in
brown), poorly differentiated invasive carcinomas (PDICs) are negative for insulin staining and are highly invasive. Scale bar: 100 mm. (C) Adjacent
sections were stained for insulin and T-antigen. PDICs remained positive for T-antigen staining. Scale bar: 50 mm.
doi:10.1371/journal.pone.0064472.g001
Figure 2. PDICs exhibit a high mitotic index. (A) Adjacent tumor sections were stained for insulin and Ki67. PDICs that do not express insulin
(inset) were found to have a very large proportion of Ki67+ proliferating cells. Tumors outlined with dotted white lines on the right are insulinomas,
showing a markedly lower degree of Ki67 staining. Scale bar represents 200 mm. (B) Tumor sections were stained by immunofluorescence for insulin
and Ki67. Insulinomas (top right) exhibit significantly less Ki67 positive cells than adjacent PDICs (lower left). Scale bar: 20 mm. (C) Mitotic index was
calculated by the number of Ki67+ cells over the total cells per tumor, and tumors were stratified into insulinomas or PDICs using insulin staining. P
values were obtained using Student’s unpaired t-test.
doi:10.1371/journal.pone.0064472.g002
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of PDICs, indicating these tumors do not arise from an exocrine
cell of origin.
PDICs specifically express Id1
Characterization of PDICs revealed that they have lost multiple
markers of beta-cell differentiation, however, factors that were
specifically expressed by these tumors remained unknown. We
therefore undertook a candidate-based approach to determine a
specific, positive marker of PDICs. Due to the apparent
dedifferentiation of these tumors, we investigated the expression
pattern of Id1, one of the inhibitor of DNA binding (Id) proteins.
Id1 has been shown to inhibit differentiation, to stimulate
proliferation and to be expressed by embryonic stem cells, adult
stem cells and cancer stem cells [19–21], thus making it a logical
candidate to investigate.
We stained tissue sections from RT2 mice and found that Id1
was expressed in all endothelial cells within tumors (Figure 5A),
which was expected as Id1 has been shown to play an important
role in tumor angiogenesis [22]. Tumor cells in insulinomas had
no detectable Id1 staining (Figure 5A). Strikingly, we found that
the majority of tumor cells in PDICs specifically stained for Id1,
exhibiting a nuclear staining pattern (Figure 5A). We also found
that tumor cells in PDICs specifically were positive for Id3
(Figure 5A), another Id family member which can play a
redundant role to Id1 [19]. By staining each of the PDICs that
had been previously identified by their loss of insulin, we
determined that tumor cells in all PDICs were positive for Id1.
In addition, through immunofluorescence co-staining we found
that Id1 expression was mutually exclusive from insulin expression
(Figure 5B). While the majority of PDIC tumors were found to be
entirely positive for Id1, we found two instances in which Id1 was
regionally expressed; for example, present only in tumor cells
along the invasive front of the PDIC, with the remainder of the
tumor only having Id1 expression in endothelial cells (Figure 5C).
Interestingly, we also observed several tumors in which Id1
nuclear staining was found in the exocrine cells directly adjacent to
a PDIC (Figure 5D), while we never saw exocrine Id1 staining in
any other instance.
Additionally, we confirmed the expression of Id1 in protein
lysates from a panel of RT2 tumors (Figure 6A). Most tumors
showed moderate levels of Id1, most likely originating from the Id1
produced by endothelial cells within the vasculature of the tumor.
Interestingly, one tumor showed much higher levels of Id1
(Figure 6A, lane #5). Consistent with the immunohistochemistry
staining of PDICs (Figure 3), we found that this tumor had
corresponding absences of insulin and MafA expression
(Figure 6A).
A previous study has suggested that in the RT2 model, a subset
of tumors may arise through a distinct pathway, termed ‘‘met-like
primary’’ (MLP) tumors [12]. It was proposed that these MLPs
most likely occur through a divergent branch during tumorigen-
esis, separate from the multistage progression from encapsulated to
invasive classes of tumors. The relatively low frequency of MLPs,
also constituting ,10% of the tumors profiled [12], and showing a
distinct gene signature from the majority of the tumors, raised the
interesting possibility that met-like primary tumors are in fact
PDICs.
To investigate whether MLPs exhibited similar markers to
PDICs, we analyzed the expression of specific Id family members
in RNA in tumors that had previously been identified as MLPs
based on a previously reported gene signature (Olson et al., 2009).
We found that expression of Id1 and Id2 were significantly
upregulated in MLPs, as compared to invasive tumors (IT)
(Figure 6B). These results suggest that MLPs and PDICs may
indeed be the same type of tumor, potentially representing a
common and separate pathway for these more aggressive tumors
compared to other classes of tumors in this model.
Discussion
Identification of PDICs in RT2 mice
We have described the discovery of a class of tumors, PDICs,
which have lost markers of beta-cell differentiation, are highly
proliferative and anaplastic. Intriguingly, this tumor type exhibits
many of the characteristics of high grade PD-PanNETs, a tumor
subset of which very little is known and for which patients have
very poor prognosis. Studying these tumors may thus provide
important insights into the molecular mechanisms of PD-
PanNETs.
Having serendipitously discovered these tumors through their
loss of insulin expression, we first further characterized these
tumors histologically. We found that PDICs had not only lost
insulin expression, but did not express many markers of beta-cell
differentiation, including those that are expressed in progenitor
cells during development. MafA is a transcription factor respon-
sible for insulin activation and is expressed only in mature beta-
cells [14]; thus its absence in RT2 PDICs was consistent with the
loss of insulin. Two other transcription factors were found to be
absent: Nkx6.1 and Pdx1. Nkx6.1 is turned on in endocrine cell
progenitors, remains expressed during differentiation and is
important for endocrine differentiation [14]. Pdx1 has been shown
to be essential for pancreatic development and beta-cell matura-
tion and is expressed in pancreatic progenitors and in immature
and mature beta-cells [14]. Interestingly, synaptophysin, which is
expressed by many cells of the neuroendocrine and neural lineage
[13], maintains at least some expression in PDICs, suggesting that
there is still maintenance of some aspects of their neuroendocrine
specification.
We also excluded the possibility that these tumors were derived
from, or trans-differentiated into, a different cell type within the
pancreas by staining for markers of other pancreatic neuroendo-
crine cells and acinar cells. PDICs did not express markers of
alpha-cells or delta-cells, and maintained expression of T-antigen.
It is intriguing that tumors that have lost insulin expression still
maintain T-antigen expression, as its expression is driven by the
rat insulin promoter (RIP), which is controlled in a similar manner
to that of the endogenous mouse insulin gene. The mechanism of
this silencing of insulin expression remains an open question.
The inhibitor of DNA binding family member Id1 was the first
protein that we identified as being specifically expressed in PDICs.
Id1 has been shown to be expressed by adult neural stem cells and
Table 1. Frequency of poorly differentiated invasive
carcinomas (PDICs) in RT2 mice.
RT2 Mice RT2 Tumors
Total Analyzed 10 86
PDIC 7 9
Percentage PDIC 70% 10.3%
RT2 pancreata were serially sectioned and every 10th slide was stained for
insulin to identify PDICs, determined by loss of insulin expression. PDICs were
confirmed by expression of Id1. RT2 mice have multiple tumors, thus the
frequency of PDIC incidence per mouse and as a percentage of all tumors was
calculated (70% and 10.3% respectively).
doi:10.1371/journal.pone.0064472.t001
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Figure 3. PDICs exhibit loss of multiple neuroendocrine markers. Tissue sections were stained for the following markers of neuroendocrine
differentiation: Synaptophysin, ChromograninA, MafA, Nkx6.1 and Pdx1, and representative images are shown. While insulinomas all stained positive
Identification of PDICs in a Mouse Model
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glioma stem cells [20,21]. This, combined with the loss of markers
of endocrine progenitors, raises the interesting possibility that these
tumors may have stem cell-like properties, or perhaps have arisen
from a pancreatic progenitor cell, however these possibilities
remain to be investigated.
How do PDICs develop?
Having identified and characterized PDICs histologically, we
were interested in understanding how they develop. There are
several hypotheses as to how these tumors may arise. PDICs could
result from a further progression from the invasive IC2 class of
carcinomas, in which loss of differentiation markers has occurred
during the progression to a high-grade tumor. Alternatively,
PDICs could represent a separate tumorigenesis pathway, in
which they progress without beta-cell markers in a distinct
development pathway to insulinomas. Similarly, PDICs could
represent a completely different tumor type, derived from a
different cell of origin, whether it be a stem or progenitor cell or
another pancreatic neuroendocrine cell.
We have made several interesting observations that could
provide insight into these possibilities regarding the development
of PDICs. The majority of PDICs were found to be entirely Id1+,
suggesting that tumors arose from a single clone, consistent with
the hypothesis that these tumors originated through a separate
pathway or cell of origin to the other classes of RT2 tumor.
However, we found that occasional tumors exhibited Id1+ cells
only at the invasive edges of the tumor. This could be indicative of
the progression of an invasive tumor cell population that has lost
insulin expression, and gained Id1 expression. Alternatively, it
could again represent a subset of tumor cells that have arisen from
for these markers (left panels, detected by DAB in brown), PDICs exhibited either complete or heterogeneous loss of these markers (right panels). T =
tumor, E = exocrine pancreas. Scale bars: 50 mm.
doi:10.1371/journal.pone.0064472.g003
Figure 4. PDICs do not express alpha-cell, delta-cell or exocrine cell markers. (A, B) Tissues were stained for glucagon, to label alpha-cells,
and somatostatin, to label delta-cells. Normal islets showed the expected expression pattern for these markers at the periphery of islets (detected by
DAB in brown). PDICs were negative for these pancreatic endocrine cell markers, exhibiting staining in rare alpha-cells or delta-cells seen within the
tumor and with non-specific background staining in exocrine cells. (C) Tissues were stained for elastase, which labels acinar cells in the exocrine
pancreas. Positively stained cells are labeled in brown, and were only observed in the exocrine tissue (E), never in the PDIC tumors (T). Scale bar:
50 mm.
doi:10.1371/journal.pone.0064472.g004
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Figure 5. Id1 is expressed by tumor cells in PDICs. (A) Paraffin sections were stained for Id1 and Id3 and representative images are shown. PDIC
tumor cells specifically expressed Id1 and Id3, while insulinoma tumor cells did not, with Id1 and Id3 staining only detectable in endothelial cells as
expected. Scale bar: 50 mm. (B) Id1 and insulin expression are mutually exclusive by immunofluorescence staining. Scale bar: 20 mm. (C) Id1+ cells
(brown) are evident at the invasive front of a tumor, and (D) Id1 staining is observed in exocrine cells adjacent to a PDIC (indicated by white arrows).
Scale bar: 50 mm.
doi:10.1371/journal.pone.0064472.g005
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a PDIC clone, which is present at the tumor edge. The observation
that PDICs exhibit a high mitotic index also brings into question
the timing of their development. With high proliferation rates, it
would be expected that PDICs would grow at a much faster rate
than insulinomas. However, PDICs are not any larger on average
than insulinomas, suggesting that they may arise later than
insulinomas. Thus, the development of these tumors remains an
interesting, open question and could provide important insights
into the development of patient PD-PanNETs.
Due to the similarly low ,10% frequency of PDICs found in
our study and the previously described met-like primary (MLP)
tumors [12], we were intrigued as to whether these tumors were
the same. Interestingly, we found that Id1 and Id2 are expressed
highly in MLP RT2 tumors, suggesting that PDICs may indeed
represent the same lesion as MLPs. It has been previously
proposed that MLPs develop through a distinct development
pathway to other invasive tumors [12]. This is consistent with our
observation that the majority of PDICs are entirely insulin
negative, and thus unlikely to have progressively ‘lost’ insulin
expression during the course of multistage tumorigenesis. It will be
interesting in future studies to investigate an extensive panel of
endocrine markers in MLPs, including insulin and several of the
beta-cell specific genes analyzed here, to definitively determine if
MLPs and PDICs are the same class of tumor.
Implications for PD-PanNET patients
Surgical resection is the most effective treatment option for
PanNETs; however, approximately 65% of patients present with
unresectable or metastatic disease. PD-PanNETs respond very
differently to therapeutic agents than well-differentiated PanNETs
and thus are treated with a different regimen. PD-PanNETs are
generally managed with surgery and platinum-based chemother-
apy [23]. Unfortunately, little is currently known about how to
stratify patients based on their prognosis, nor the use of targeted
therapies for PD-PanNETs with unresectable metastases. The
RT2 model has been shown to have critical predictive value for
clinical studies, predicting response to the recently FDA-approved
drugs sunitinib malate and everolimus for well-differentiated
PanNETs [24–27]. Previously, studies in the RT2 model have
been used to investigate the behavior of well-differentiated
Figure 6. PDICs and ‘‘met-like primary’’ tumors have high expression of Id1. (A) A panel of protein lysates from individual RT2 tumors was
blotted for Id1, insulin and MafA, with actin as a loading control. The tumor lysate #5 is a PDIC, as it has high Id1 levels with absence of insulin and
MafA protein expression. (B) Expression of Id1 and Id2 were examined in RNA from invasive tumors (IT) and ‘‘met-like primary’’ tumors (MLP) from the
RT2 model, and calculated compared to the housekeeping gene RPL13A. Both Id1 and Id2 are expressed at significantly higher levels in MLP
compared to IT tumors. n= 4 tumors for each group. P values were obtained using Student’s unpaired t-test.
doi:10.1371/journal.pone.0064472.g006
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PanNETs. Our identification of PDICs in this model that mimic
many characteristics of PD-PanNETs in patients now offers a
unique opportunity to explore the pathology and molecular
characteristics of this aggressive tumor type.
Materials and Methods
Transgenic mice and tissue processing
The generation and characterization of RIP1-Tag2 (RT2) [7]
mice has been previously reported. All animal studies were
performed using protocols approved by the Animal Care
Committee at Memorial Sloan-Kettering Cancer Center. RT2
mice were sacrificed by heart perfusion with PBS followed by 10%
zinc-buffered formalin. Tumor-containing pancreas and control
tissues were removed, formalin-fixed overnight, processed through
an ethanol series, embedded in paraffin blocks and paraffin
sections (5 mm) were cut on a microtome.
Immunohistochemistry (IHC) and immunofluorescence
(IF) staining
Paraffin sections were stained using DAB detection with a
Discovery XT automated staining processor (Ventana Medical
Systems, Inc). For immunofluorescence staining, paraffin sections
were processed with a Discovery XT automated staining
processor, incubated with the primary antibody of interest
overnight at 4uC, incubated with the corresponding fluores-
cently-tagged secondary antibody for 1 hour at room temperature,
incubated with 46-diamidino-2-phenyl indole (DAPI) for 10 min-
utes and mounted with ProLong Gold (Invitrogen). Tissue sections
were visualized under a Carl Zeiss Axioimager Z1 microscope and
images were acquired with Axiovision using an Apotome (Zeiss) or
with TissueFAXS (TissueGnostics, Vienna, Austria). For the
proliferation analysis, the quantitation was performed using
HistoQuest software (TissueGnostics) to determine the percentage
of Ki67+ cells. The following antibodies were used for IF and IHC
staining: rabbit anti-SV40 T antigen (Santa Cruz, 1:500), guinea
pig anti-insulin (DAKO, 1:1000), rabbit anti-synaptophysin
(DAKO, 1:200), rabbit anti-Ki67 (Vector, 1:200), rabbit anti-
chromogranin A (Abcam 1:250), rabbit anti-MafA (Abcam, 1:500),
anti-Nkx6.1, rabbit anti-Pdx1 (Abcam, 1:500), rabbit anti-gluca-
gon (Millipore 1:1000), rabbit anti-somatostatin (DAKO, 1:500),
rabbit anti-elastase (Abcam, 1:2000), rabbit anti Id1 (BioCheck,
1:200) and rabbit anti-Id3 (BioCheck, 1:200). Relevant species-
specific IgG controls for each antibody were stained in parallel,
and no non-specific staining was observed.
Western blotting
Protein lysates were made from dissected RT2 tumors using
RIPA lysis buffer. 40 mg of protein was loaded onto SDS-PAGE
gels and transferred to PVDF membranes for immunoblotting.
Membranes were probed with antibodies against Id1 (BioCheck
1:500), insulin (DAKO 1:1000), MafA (Abcam 1:1000) and actin
(Sigma, 1:5000) and detected using HRP-conjugated anti-guinea
pig or anti-rabbit (Jackson Immunoresearch) antibodies using
chemiluminescence detection (Amersham).
Gene expression analysis in RT2 tumors
RNA was isolated from different tumors (invasive tumors (IT)
and ‘‘met-like primary’’ tumors (MLPs)) from the RT2 mouse
model and reverse transcription was performed as described [12].
Quantitative real-time RT-PCR was performed using Rotor-Gene
(Qiagen) as per the instructions from the manufacturer. DD(cycle
threshold)ct values were calculated after normalizing the ct values
for each individual gene to that of the housekeeping gene,
RPL13A, as described [28].
Statistical analysis
Throughout this study, means +/2 SEM (standard error of the
mean) are reported unless otherwise specified. For all two-way
comparisons, unpaired t-tests were used and were considered
statistically significant if P,0.05.
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